

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6845225

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TAO PEI	05/17/2021
CASI SCHIENEBECK	05/10/2021
ZHAO XU	05/13/2021
ANTHONY NICHOLAS	04/21/2021
ZHI-MING DING	05/17/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ARROWHEAD PHARMACEUTICALS, INC.
<b>Street Address:</b>	177 E. COLORADO BOULEVARD
<b>Internal Address:</b>	SUITE 700
<b>City:</b>	PASADENA
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	91105
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17213787
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(215)568-3439
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2155683100
<b>Email:</b>	patents@bakerlaw.com
<b>Correspondent Name:</b>	BAKER & HOSTETLER LLP
<b>Address Line 1:</b>	2929 ARCH STREET
<b>Address Line 2:</b>	CIRA CENTRE, 12TH FLOOR
<b>Address Line 4:</b>	PHILADELPHIA, PENNSYLVANIA 19104-2891
<b>ATTORNEY DOCKET NUMBER:</b>	103693.002474
<b>NAME OF SUBMITTER:</b>	DENISE MARVEL
<b>SIGNATURE:</b>	/Denise Marvel/
<b>DATE SIGNED:</b>	08/03/2021
This document serves as an Oath/Declaration (37 CFR 1.63).	

PATENT

**Total Attachments: 10**

source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page1.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page2.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page3.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page4.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page5.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page6.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page7.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page8.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page9.tif  
source=103693\_002474\_Combined\_Declaration\_and\_Assignments\_signed#page10.tif

## COMBINED DECLARATION AND ASSIGNMENT

**Title of Invention:** RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use

This declaration and assignment is directed to:

- ☒ The United States application or PCT international application number 17/213,787 filed on March 26, 2021 and PCT/US2021/024299 filed March 26, 2021.

### Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

### Assignment

**ARROWHEAD PHARMACEUTICALS, INC.**  
177 E. Colorado Boulevard, Suite 700  
Pasadena, California 91105 US

A corporation of the state or country of Delaware  
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of March 26, 2020:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.


I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Tao Pei



Signature

17 May 2021

Date

## COMBINED DECLARATION AND ASSIGNMENT

**Title of Invention:** RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use

This declaration and assignment is directed to:

- ☒ The United States application or PCT international application number 17/213,787 filed on March 26, 2021 and PCT/US2021/024299 filed March 26, 2021.

### Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

### Assignment

**ARROWHEAD PHARMACEUTICALS, INC.**  
177 E. Colorado Boulevard, Suite 700  
Pasadena, California 91105 US

A corporation of the state or country of Delaware  
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of March 26, 2020:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.


I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Casi Schienebeck

  
Signature

  
Date

## COMBINED DECLARATION AND ASSIGNMENT

**Title of Invention:** RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use

This declaration and assignment is directed to:

- ☒ The United States application or PCT international application number 17/213,787 filed on March 26, 2021 and PCT/US2021/024299 filed March 26, 2021.

### Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

### Assignment

**ARROWHEAD PHARMACEUTICALS, INC.**  
177 E. Colorado Boulevard, Suite 700  
Pasadena, California 91105 US

A corporation of the state or country of Delaware  
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of March 26, 2020:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Zhao Xu

1 Zhao Xu 1

Signature

5/13/2021

Date



## COMBINED DECLARATION AND ASSIGNMENT

**Title of Invention:** RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use

This declaration and assignment is directed to:

- ☒ The United States application or PCT international application number 17/213,787 filed on March 26, 2021 and PCT/US2021/024299 filed March 26, 2021.

### Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

### Assignment

**ARROWHEAD PHARMACEUTICALS, INC.**  
177 E. Colorado Boulevard, Suite 700  
Pasadena, California 91105 US

A corporation of the state or country of Delaware  
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of March 26, 2020:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Anthony Nicholas



Signature

4/21/2021

Date

## COMBINED DECLARATION AND ASSIGNMENT

**Title of Invention:** RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use

This declaration and assignment is directed to:

- ☒ The United States application or PCT international application number 17/213,787 filed on March 26, 2021 and PCT/US2021/024299 filed March 26, 2021.

### Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

### Assignment

**ARROWHEAD PHARMACEUTICALS, INC.**  
177 E. Colorado Boulevard, Suite 700  
Pasadena, California 91105 US

A corporation of the state or country of Delaware  
(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee, such assignment being made effective as of March 26, 2020:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Zhi-Ming Ding

  
Signature

  
Date